Market Overview

UPDATE: Jefferies Raises PT on Endo Health Following DeSilva Public Appearance

Related ENDP
5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm
Endo Bought Par In One Of Biggest Generics M&A Deals Ever: What The Street's Saying
Merck KGaA's Pipeline on Track, Updates Key R&D Projects (Zacks)

In a report published Friday, Jefferies analyst Corey Davis reiterated a Buy rating on Endo Health Solutions (NASDAQ: ENDP), and raised the price target from $37.00 to $45.00.

In the report, Jefferies noted, “ENDP CEO Rajiv DeSilva made his 1st public appearance at our conference today. Despite <4 months as CEO, Mr. DeSilva showed an impressive grasp of the business and inspired confidence in his new model: 1) M&A will be a clear focus, 2) the decentralized ‘lean pharma' model is gaining credibility, & 3) a worst-case scenario now yields $3.58 EPS as a trough in 2014 before growth after '15. Raise target to $45.”

Endo Health Solutions closed on Thursday at $35.96.

Latest Ratings for ENDP

Sep 2015NomuraInitiates Coverage onBuy
Sep 2015Deutsche BankInitiates Coverage onBuy
Sep 2015Morgan StanleyDowngradesOverweightEqual-weight

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Corey Davis JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (ENDP)

View Comments and Join the Discussion!

Get Benzinga's Newsletters